Leerink Partnrs Has Optimistic Outlook of A Q3 Earnings

Agilent Technologies, Inc. (NYSE:A) – Leerink Partnrs increased their Q3 2025 EPS estimates for Agilent Technologies in a research note issued on Wednesday, December 18th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of $1.42 for the quarter, up from their prior estimate of $1.41. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q1 2026 earnings at $1.49 EPS, Q2 2026 earnings at $1.43 EPS, Q3 2026 earnings at $1.52 EPS and Q4 2026 earnings at $1.66 EPS.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.41 by $0.05. The company had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. Agilent Technologies’s quarterly revenue was up .8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 EPS.

Other equities research analysts have also recently issued reports about the stock. Bank of America lowered their price objective on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Wells Fargo & Company lowered their price target on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a report on Monday, December 9th. Barclays reduced their price objective on Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating on the stock in a report on Wednesday, November 27th. JPMorgan Chase & Co. lowered their target price on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a report on Tuesday, November 26th. Finally, Evercore ISI raised their price target on Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $143.62.

Agilent Technologies Stock Up 1.0 %

Shares of NYSE:A opened at $134.51 on Monday. The firm has a market capitalization of $38.65 billion, a PE ratio of 30.43, a price-to-earnings-growth ratio of 4.48 and a beta of 1.07. The business has a 50 day simple moving average of $135.85 and a two-hundred day simple moving average of $136.48. Agilent Technologies has a 1 year low of $124.16 and a 1 year high of $155.35. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58.

Institutional Investors Weigh In On Agilent Technologies

Several large investors have recently bought and sold shares of A. Massachusetts Financial Services Co. MA boosted its position in Agilent Technologies by 3.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company’s stock worth $2,314,784,000 after acquiring an additional 525,214 shares during the last quarter. State Street Corp lifted its stake in Agilent Technologies by 1.2% in the 3rd quarter. State Street Corp now owns 12,819,897 shares of the medical research company’s stock worth $1,903,498,000 after purchasing an additional 158,175 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Agilent Technologies by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 6,948,679 shares of the medical research company’s stock worth $1,028,241,000 after purchasing an additional 30,610 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Agilent Technologies by 6.6% in the third quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock valued at $442,011,000 after purchasing an additional 183,716 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Agilent Technologies by 4.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,948,536 shares of the medical research company’s stock valued at $437,799,000 after purchasing an additional 136,184 shares during the last quarter. 87.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. This represents a 19.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.33% of the stock is owned by corporate insiders.

Agilent Technologies Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 22nd. Stockholders of record on Tuesday, December 31st will be paid a $0.248 dividend. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.74%. Agilent Technologies’s dividend payout ratio is presently 22.40%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.